Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, announced today the addition of University of Texas Medical Branch (UTMB) at Galveston as the fifth trial site in its pilot feasibility study “MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue” (NCT02680535).
